Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?  

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Florida Cancer Specialists
Did PROpel include patients who have been treated ...
Medical Oncologist at Carle Illinois College of Medicine
In PROpel, about 24% of patients had received prio...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice